NLRP3 inhibitor (Tenvie Therapeutics)

N/A

Report date: 2025/03/03 16:41:25
NME

Base Information

Drug NameNLRP3 inhibitor (Tenvie Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsMetabolic DiseasesEye DiseasesPeripheral Nervous System Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTenvie Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTenvie Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMetabolic DiseasesPeripheral Nervous System Diseases
Inactive IndicationsEye DiseasesNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A